Edwards Lifesciences breaks ground on heart valve manufacturing facility in Singapore

By Lisa Kerner

Erie, Pa., March 1 - Edwards Lifesciences Corp. said construction will begin immediately on its new 98,000-square-foot heart valve manufacturing facility in Changi North, Singapore.

Edwards said it will continue to operate in a temporary facility in Kaki Bukit, Singapore, until the state-of-the-art facility is completed in October 2007. It will be the company's third global manufacturing facility dedicated to producing Edwards' Carpentier-Edwards Perimount replacement tissue heart valves, according to a company news release.

"Edwards Lifesciences is dedicated to providing the world's highest quality, most technologically advanced replacement heart valves, and we expect this new facility will help us meet the growing demands of advanced cardiovascular disease patients," said Corinne H. Lyle, president of global operations, in the release.

The new Singapore plant will use advanced heart valve manufacturing technologies to serve patients from the Asia Pacific region, officials said.

Based in Irvine, Calif., Edwards focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.